Health Institute Carlos III
If you are the contact person for this centre and you wish to make any changes, please contact us.
Head of the Influenza and other Respiratory Virus Surveillance Group of the National Epidemiology Centre.
Researcher at the Reference and Research Laboratory in Mycology, National Microbiology Centre, Instituto de Salud Carlos III
Senior Scientist at the Health Institute Carlos III
Researcher in social epidemiology, public health and biostatistics
Co-director of the Reference Unit on Climate Change, Health and Urban Environment of the Carlos III Health Institute
Researcher at the National Center for Microbiology - Carlos III Health Institute
Senior scientist at the Reference Laboratory for Influenza and Respiratory Viruses of the National Microbiology Centre.
Associate Professor of Epidemiology at the Autonomous University of Madrid (UAM) and Research Scientist at the National Epidemiology Centre (Carlos III Health Institute)
Head of the Respiratory Virus and Influenza Research Group of the Carlos III Health Institute
Full university professor at the Central University Hospital of Asturias, scientific director of the Principality of Asturias Biobank (BioPA) and coordinator of the Organoid Hub of the National Platform of Biobanks and Biomodels of the ISCIII
In the last few days, data, preprints, press releases and even graphs have started to arrive via social media showing how neutralising antibodies against the omicron variant behave. These studies are preliminary and we will have to wait and see how these lab data translate into the real world.
A new variant of the coronavirus causing COVID-19 has been identified in South Africa, with numerous mutations present in other variants, including Delta. Variant B.1.1.529, as it is now called, appears to be spreading rapidly in South Africa. Attached is the rapid reaction of three Spanish researchers with expertise in genomic surveillance.
A study of more than 700,000 people in Sweden analysed the effectiveness of the heterologous schedule, combining the AstraZeneca vaccine with another dose of a messenger RNA vaccine, with the traditional homologous schedule, consisting of two doses of AstraZeneca. The results showed increased protection against SARS-CoV-2 infection when two different vaccines were combined.